Share This

PR Newswire Asia's news > Medical/Pharmaceuticals

 |   Title only   |   Print    Next page > 
     
United Imaging Prepares to Ship its 30,000th Unit Globally, a uMI Panorama GS, from Houston for U.S. Installation
The uMI Panorama GS is among the all-digital Molecular Imaging systems United Imaging  is featuring at SNMMI in Toronto ...
2024-06-08T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal
SEOUL, South Korea , June 7, 2024 /PRNewswire/ -- Dear Fellow Shareholders, ...
2024-06-07T    Health Care/Hospital   Medical/Pharmaceuticals 
deCODE genetics: The rate, nature and transmission of mitochondrial DNA mutations in humans
A new study from deCODE genetics uses pedigrees and sequence data from 64,806 Icelanders to shed light on the rate and nature of mutations in mitochondrial DNA (mtDNA) and the peculiar dynamics of its ...
2024-06-07T    Biotechnology   Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
THRIVING BEYOND CANCER: Pantai Hospital Kuala Lumpur's Heartfelt Month of Celebration and Support to Cancer Survivors with Special June Activities
KUALA LUMPUR, Malaysia , June 7, 2024 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL), a beacon of medical excellence and compassionate patient care, proudly announces a series of events in celebration ...
2024-06-07T    Entertainment   Film & Motion Picture   Health Care/Hospital   Medical/Pharmaceuticals 
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
New translational data  demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection ...
2024-06-07T    Biotechnology   Health Care/Hospital   Infectious Disease Control   Medical/Pharmaceuticals 
EASL Wrap-up Session Highlighted Late-Breaking Clinical Data of First-in-class HBV-specific TCR T Cell Therapy (SCG101) Showing Improved Overall Survival in HBV-related Hepatocellular Carcinoma
SINGAPORE , June 7, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, ...
2024-06-07T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
MLB Announces IND Approval by US FDA to Initiate Phase 1 Trial of TML-6, a New Era Multi-Target Drug for the Treatment of Alzheimer's Disease
TAINAN, June 7, 2024 /PRNewswire/ -- MLB (Merry Life Biomedical Company, Ltd., Taiwan : https://www.tmlbio.com/ ), a biomedical company, announced that the U.S. Food and Drug Administration (FDA) has ...
2024-06-07T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024
JINAN, China , June 6, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting convened from May 31 to June 4, 2024 in Chicago , USA , adopting a hybrid format. ...
2024-06-07T    Health Care/Hospital   Medical/Pharmaceuticals 
Potential Add-on Treatment for Patients with Parkinson's Disease: Stimvia Completes Pilot Study and Announces Promising Initial Results
PRAGUE , June 7, 2024 /PRNewswire/ -- Stimvia , a pioneering medical technology company specializing in neuromodulation for chronic disease treatment, has successfully completed its pilot study focused ...
2024-06-07T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China
According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. MRX-8 not only ...
2024-06-06T    Health Care/Hospital   Medical/Pharmaceuticals 
  Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.